Last reviewed · How we verify
Investigator choice of standard therapy
Investigator choice of standard therapy is a Small molecule drug developed by iOnctura. It is currently in Phase 2 development.
At a glance
| Generic name | Investigator choice of standard therapy |
|---|---|
| Sponsor | iOnctura |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer (PHASE3)
- MP101 in Adults With Acute Pseudomonas Aeruginosa Pneumonia (PHASE1)
- A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma (PHASE3)
- Adjunctive Hyperbaric Oxygen Treatment for Patients With Necrotizing Soft-Tissue Infection (HOT-NSTI Trial). Investigator-initiated, International, Multicentre, Superiority, Randomized, Open-label, Clinical Trial. (PHASE4)
- Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy (PHASE2, PHASE3)
- Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer (PHASE2)
- Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies (PHASE2)
- Receptive Music Therapy Effects on Anxiety, Depression, QoL, and EGF, IL-8, and NfL During the Breast Cancer Treatment. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Investigator choice of standard therapy CI brief — competitive landscape report
- Investigator choice of standard therapy updates RSS · CI watch RSS
- iOnctura portfolio CI
Frequently asked questions about Investigator choice of standard therapy
What is Investigator choice of standard therapy?
Investigator choice of standard therapy is a Small molecule drug developed by iOnctura.
Who makes Investigator choice of standard therapy?
Investigator choice of standard therapy is developed by iOnctura (see full iOnctura pipeline at /company/ionctura).
What development phase is Investigator choice of standard therapy in?
Investigator choice of standard therapy is in Phase 2.